Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE: Aliskiren/Amlodipine Initial Combination in Hypertension
NCT00797862Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (3 arms), sponsored by Novartis. Primary endpoints: Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks and Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24. Started Nov 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00797862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00797862.